FIKRI-BENBRAHIM, Oussamah et al. Treatment with adalimumab in amyloidosis secondary to rheumatoid arthritis: two case reports. []. , 33, 3, pp.404-409. ISSN 1989-2284.  https://dx.doi.org/10.3265/Nefrologia.pre2012.Aug.11552.

Rheumatological diseases and, firstly, rheumatoid arthritis (RA) remain a major cause of secondary amyloidosis. The emergence of biological agents such as adalimumab in the early treatment of RA can be an effective alternative to stop the development and progression of secondary amyloidosis. Not all patients will respond the same way to treatment; we must consider associated comorbidity, the poor prognosis factors for predicting therapeutic response and possible adverse effects. In the adverse effects of biological therapies, there has been an increase in the rate of lethal infections and congestive heart failure. We present two cases with renal amyloidosis secondary to RA who had a different clinical course: our 1st case had a good response to Adalimumab while the 2nd case evolved unfavourably after treatment, and died from cardiovascular complications.

: Secondary amyloidosis (AA); Rheumatoid arthritis; Adalimumab.

        · |     · |     · ( pdf )